Company news

Cellectar Biosciences, Inc. news in 2020

Cellectar Biosciences, Inc.'s news releases, calls and decks from 2020, newest first.

View company

Cellectar Biosciences Announces Closing of $24.5 Million Underwritten Public Offering and $20.5 Million Concurrent Private Placement

December 27, 2020

Cellectar Biosciences Announces Pricing of $24.5 Million Underwritten Public Offering and $20.5 Million Concurrent Private Placement

December 22, 2020

Cellectar Biosciences Announces Proposed Underwritten Public Offering and Concurrent Private Placement

December 21, 2020

Cellectar Reports Third Quarter 2020 Financial Results and Provides a Corporate Update

November 8, 2020

Cellectar Biosciences’ CLR 131 Demonstrates Preliminary Activity in Phase I Study for Pediatric Brain and Solid Tumors

November 4, 2020

Cellectar Reports Data on CLR 131 Phase 2 CLOVER-1 Study in Triple Class Refractory Multiple Myeloma Patients

September 8, 2020

Cellectar Reports Second Quarter 2020 Financial Results and Provides a Corporate Update

August 9, 2020

Cellectar Announces Poster Presentation at the International Symposium on Pediatric Neuro-Oncology (ISPNO) Annual Meeting

August 3, 2020

Cellectar Announces Poster Presentation of Clinical Data at the American Association of Cancer Research (AACR) Annual Meeting

July 20, 2020

Cellectar Appoints Dr. John Friend as Chief Medical Officer

June 30, 2020

Cellectar to be Granted EU Patent for Phospholipid Ether (PLE) Analogs as Cancer-Targeting Drug Vehicles

June 10, 2020

Cellectar Biosciences Announces Closing of $20 Million Underwritten Public Offering

June 4, 2020

Cellectar Biosciences Announces Pricing of $20 Million Underwritten Public Offering

June 2, 2020

Cellectar Granted SME Status by the European Medicines Agency

May 31, 2020

Cellectar Receives FDA Fast Track Designation for CLR 131 in Lymphoplasmacytic Lymphoma/Waldenstrom’s Macroglobulinemia

May 25, 2020

Cellectar Granted Composition of Matter and Use Patent in Europe for CLR 131

May 13, 2020

Cellectar Reports First Quarter 2020 Financial Results and Provides a Corporate Update

May 6, 2020

Cellectar Reports Financial Results for Year Ended December 31, 2019 and Provides a Corporate Update

March 8, 2020

Cellectar Biosciences Announces CLR 131 Achieves Primary Efficacy Endpoints from Its Phase 2 CLOVER-1 Study in Relapsed/Refractory B-cell Lymphomas and Completion of the Phase 1 Relapsed/Refractory Multiple Myeloma Dose Escalation Study

February 18, 2020

Cellectar Biosciences to Host a CLR 131 Clinical Data Call with Its Phase 2 Lead Investigator on February 19, 2020

January 8, 2020

Cellectar Appoints Dr. Igor Grachev as Chief Medical Officer

January 6, 2020

Cellectar Receives Orphan Drug Designation for CLR 131 in Lymphoplasmacytic Lymphoma (LPL)

January 5, 2020

Decks in 2020